Moreover, Ppard interaction with hepatic AMPK (phospho-AMP-activated protein kinase), PGC-1α (PPARα-PPARγ coactivator), and lipin-1 refers to them as therapeutic targets in the prevention of dyslipidemia [51]. This evidence concerns the gene PPARA and metabolic syndrome.